{"id":"de-117-ophthalmic-solution-bid","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Eye irritation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"DE-117 Ophthalmic Solution BID works by reducing inflammation in the eye, which can help to treat conditions such as uveitis and other inflammatory eye diseases.","oneSentence":"DE-117 Ophthalmic Solution BID is an anti-inflammatory agent.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:31:41.551Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of non-infectious uveitis affecting the posterior segment of the eye"}]},"trialDetails":[{"nctId":"NCT03691649","phase":"PHASE3","title":"A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2018-09-14","conditions":"Glaucoma and Ocular Hypertension","enrollment":426},{"nctId":"NCT03691662","phase":"PHASE3","title":"A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2018-09-27","conditions":"Glaucoma and Ocular Hypertension","enrollment":417},{"nctId":"NCT03858894","phase":"PHASE2","title":"Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2019-01-28","conditions":"Primary Open-angle Glaucoma and Ocular Hypertension","enrollment":98}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"DE-117 Ophthalmic Solution BID","genericName":"DE-117 Ophthalmic Solution BID","companyName":"Santen Inc.","companyId":"santen-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DE-117 Ophthalmic Solution is used to treat Glaucoma and Ocular Hypertension, as well as Primary Open-angle Glaucoma and Ocular Hypertension. It is an oligosaccharide-based solution, with its exact mechanism of action not specified in the provided information.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}